CXorf61 is a target for T cell based immunotherapy of triple-negative breast cancer.

Oncotarget
Claudia ParetUgur Sahin

Abstract

Triple-negative breast cancer (TNBC) is a high medical need disease with limited treatment options. CD8+ T cell-mediated immunotherapy may represent an attractive approach to address TNBC. The objectives of this study were to assess the expression of CXorf61 in TNBCs and healthy tissues and to evaluate its capability to induce T cell responses. We show by transcriptional profiling of a broad comprehensive set of normal human tissue that CXorf61 expression is strictly restricted to testis. 53% of TNBC patients express this antigen in at least 30% of their tumor cells. In CXorf61-negative breast cancer cell lines CXorf61 expression is activated by treatment with the hypomethylating agent 5-aza-2'-deoxycytidine. By vaccination of HLA-A*02-transgenic mice with CXorf61 encoding RNA we obtained high frequencies of CXorf61-specific T cells. Cloning and characterization of T cell receptors (TCRs) from responding T cells resulted in the identification of the two HLA-A*0201-restricted T cell epitopes CXorf6166-74 and CXorf6179-87. Furthermore, by in vitro priming of human CD8+ T cells derived from a healthy donor recognizing CXorf6166-74 we were able to induce a strong antigen-specific immune response and clone a human TCR recognizing th...Continue Reading

References

Dec 22, 1999·Immunogenetics·H RammenseeS Stevanović
Aug 30, 2000·Nature·C M PerouD Botstein
Nov 26, 2002·Immunological Reviews·Matthew J ScanlanYao-Tseng Chen
Aug 17, 2004·Cancer Immunology, Immunotherapy : CII·Luisa NovellinoGiorgio Parmiani
Aug 3, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Rebecca DentSteven A Narod
Apr 24, 2008·Molecular Therapy : the Journal of the American Society of Gene Therapy·Aude BonehillKris Thielemans
Dec 18, 2008·Proceedings of the National Academy of Sciences of the United States of America·Oliver HofmannWinston Hide
Jul 15, 2009·Clinical Breast Cancer·Carey K Anders, Lisa A Carey
Aug 5, 2009·Proceedings of the National Academy of Sciences of the United States of America·Anita GrigoriadisA Munro Neville
Sep 2, 2009·Cancer Science·Otavia L Caballero, Yao-Tseng Chen
Jul 9, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G CuriglianoA Goldhirsch
Feb 10, 2011·The Oncologist·Clifford A Hudis, Luca Gianni
Mar 17, 2012·Breast Cancer Research : BCR·Shuzhen LiuTorsten O Nielsen
Feb 5, 2013·Journal of Immunotherapy·Richard A MorganSteven A Rosenberg
Aug 13, 2014·World Journal of Clinical Oncology·Meng Zhao, Bhuvaneswari Ramaswamy

❮ Previous
Next ❯

Citations

Feb 18, 2020·World Journal of Gastroenterology : WJG·Akiko ShidaYoshihito Takahashi
Sep 29, 2020·Frontiers in Immunology·Mie K Jakobsen, Morten F Gjerstorff
Jan 2, 2018·World Journal of Gastroenterology : WJG·Nobue FutawatariMasahiko Watanabe
Nov 9, 2016·Oncotarget·Chang ZouLi Fu
Aug 29, 2019·Journal for Immunotherapy of Cancer·Bridget MarcinkowskiChristian S Hinrichs
Apr 19, 2018·Scientific Reports·Takashi FukuyamaNoritada Kobayashi
Sep 4, 2020·Cancer Research and Treatment : Official Journal of Korean Cancer Association·Jiahui ChenJiafu Ji
Jun 13, 2021·Otolaryngologic Clinics of North America·Scott M Norberg, Christian S Hinrichs
Jan 12, 2021·Molecular Oncology·Soazik P JaminMichael Primig

❮ Previous
Next ❯

Methods Mentioned

BETA
RNA-seq
xenografting
xenograft
flow cytometry
density gradient centrifugation
PCR
PCRs
electrophoresis
scraping

Software Mentioned

Quest
IMGT

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.